Imatinib Mesylate Dose Adjustment Based on Body Surface Area for CML Chronic Phase Patients Intolerant to Standard Dosage

Publisher： Karger

E-ISSN： 1421-9662|134|1|59-68

ISSN： 0001-5792

Source： Acta Haematologica, Vol.134, Iss.1, 2015-04, pp. : 59-68

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Reduced Dose of Imatinib for Patients with Chronic Myeloid Leukemia and Low Body Surface Area

By  

Acta Haematologica, Vol. 118, Iss. 4, 2007-11 ,pp. : 219-221

Karger

Access to resources Recommend Favorite

The Importance of Body Surface Area at Baseline and during Treatment in Chronic Myeloid Leukemia Patients Treated with Imatinib

By  

Acta Haematologica, Vol. 134, Iss. 1, 2015-04 ,pp. : 57-58

Karger

Access to resources Recommend Favorite

Management of Imatinib-Resistant CML Patients

By  

Oncology Research and Treatment, Vol. 30, Iss. 11, 2007-10 ,pp. : 574-580

Karger

Access to resources Recommend Favorite

Sustained Response to Low-Dose Imatinib Mesylate in a Patient with Chronic Myelomonocytic Leukemia with t(5;12)(q33;p13)

By  

Acta Haematologica, Vol. 119, Iss. 1, 2008-02 ,pp. : 57-59

Karger

Access to resources Recommend Favorite

Apoptosis-Related Gene Expression Profile in Chronic Myeloid Leukemia Patients after Imatinib Mesylate and Dasatinib Therapy

By  

Acta Haematologica, Vol. 133, Iss. 4, 2015-02 ,pp. : 354-364

Karger

Access to resources Recommend Favorite